So probably the ones with better documentation and stability would be the choice.

We apply the risk scores to BioVU and All of Us biobanks to accurately prediction the progression to System Lupus Erythematosus and Rheumatoid Arthritis.

We propose a new approach called Genetic Progression Score (GPS) that can borrow strengths from the large sample size of case-control studies and more accurately predict the progression from the preclinical stage to disease.